JP2023514992A5 - - Google Patents

Info

Publication number
JP2023514992A5
JP2023514992A5 JP2022548518A JP2022548518A JP2023514992A5 JP 2023514992 A5 JP2023514992 A5 JP 2023514992A5 JP 2022548518 A JP2022548518 A JP 2022548518A JP 2022548518 A JP2022548518 A JP 2022548518A JP 2023514992 A5 JP2023514992 A5 JP 2023514992A5
Authority
JP
Japan
Prior art keywords
approximately
weeks
formulation according
liquid
dosage formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514992A (ja
JP7752619B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/018947 external-priority patent/WO2021168386A1/en
Publication of JP2023514992A publication Critical patent/JP2023514992A/ja
Publication of JP2023514992A5 publication Critical patent/JP2023514992A5/ja
Priority to JP2025162266A priority Critical patent/JP2026021305A/ja
Application granted granted Critical
Publication of JP7752619B2 publication Critical patent/JP7752619B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548518A 2020-02-21 2021-02-21 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法 Active JP7752619B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025162266A JP2026021305A (ja) 2020-02-21 2025-09-29 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062980093P 2020-02-21 2020-02-21
US62/980,093 2020-02-21
US202063122108P 2020-12-07 2020-12-07
US63/122,108 2020-12-07
US202163133540P 2021-01-04 2021-01-04
US63/133,540 2021-01-04
PCT/US2021/018947 WO2021168386A1 (en) 2020-02-21 2021-02-21 Glp-1r and gcgr agonists, formulations, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025162266A Division JP2026021305A (ja) 2020-02-21 2025-09-29 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法

Publications (3)

Publication Number Publication Date
JP2023514992A JP2023514992A (ja) 2023-04-12
JP2023514992A5 true JP2023514992A5 (cg-RX-API-DMAC10.html) 2024-03-01
JP7752619B2 JP7752619B2 (ja) 2025-10-10

Family

ID=77391258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548518A Active JP7752619B2 (ja) 2020-02-21 2021-02-21 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法
JP2025162266A Pending JP2026021305A (ja) 2020-02-21 2025-09-29 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025162266A Pending JP2026021305A (ja) 2020-02-21 2025-09-29 Ｇｌｐ－１ｒおよびｇｃｇｒアゴニスト、製剤、ならびに使用方法

Country Status (11)

Country Link
US (2) US20210290732A1 (cg-RX-API-DMAC10.html)
EP (1) EP4106796A4 (cg-RX-API-DMAC10.html)
JP (2) JP7752619B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220143923A (cg-RX-API-DMAC10.html)
CN (1) CN115427065A (cg-RX-API-DMAC10.html)
AU (1) AU2021224246A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022016470A2 (cg-RX-API-DMAC10.html)
CA (1) CA3168001A1 (cg-RX-API-DMAC10.html)
IL (1) IL295744A (cg-RX-API-DMAC10.html)
MX (1) MX2022010320A (cg-RX-API-DMAC10.html)
WO (1) WO2021168386A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
US20230317230A1 (en) * 2019-05-02 2023-10-05 Closed Loop Medicine Ltd. Method for treating obesity
CN117202924A (zh) * 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法
US20240148879A1 (en) * 2021-02-21 2024-05-09 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
KR20240118786A (ko) * 2021-12-01 2024-08-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Glp-1 및 gip 수용체 이중 작용제의 약학적 조성물 및 이의 용도
KR20250067161A (ko) * 2022-09-14 2025-05-14 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
WO2024098071A1 (en) * 2022-11-05 2024-05-10 Spitfire Pharma Llc Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280814A1 (en) 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
EP4286400A3 (en) * 2011-05-18 2024-06-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014081872A1 (en) * 2012-11-20 2014-05-30 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
EP2922877B1 (en) * 2012-11-20 2018-09-05 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
BR112015025464A2 (pt) * 2013-04-18 2017-10-10 Novo Nordisk As coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
PE20170471A1 (es) 2014-06-13 2017-05-14 Santa Maria Biotherapeutics Inc Polipeptidos receptores formulados y metodos relacionados
JP2017517549A (ja) * 2014-06-13 2017-06-29 サノフイ 活性薬剤成分のナノカプセル製剤
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
FI3322437T3 (fi) * 2015-06-30 2024-02-20 Hanmi Pharmaceutical Co Ltd Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus
BR112018017031A2 (pt) 2016-02-23 2019-01-22 Sesen Bio Inc formulações de antagonista de il-6 e usos das mesmas
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders

Similar Documents

Publication Publication Date Title
US20230226141A1 (en) Angiotensin ii alone or in combination for the treatment of hypotension
ES2316567T3 (es) Adeponectina para la regeneracion hepatica.
US8071368B2 (en) Methods for promoting growth and survival of insulin-secreting cells
CN118453597A (zh) 用于治疗非酒精性脂肪性肝病和非酒精性脂肪性肝炎的组合物
JP2024545887A5 (cg-RX-API-DMAC10.html)
US20230092769A1 (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs
EP1137414A1 (en) Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
Banerjee et al. A novel peptide nanomedicine for treatment of pancreatogenic diabetes
AU2018372709B2 (en) Methods of using and compositions containing dulaglutide
WO2024042518A1 (en) Glp-1 receptor antagonist and methods of use thereof
Keenan et al. Prolonged corticotrophic action of a synthetic substituted α1-18 ACTH
Watanabe et al. ACTH response in rats during biphasic fever induced by interleukin-1
US20160303199A1 (en) Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound
JP2026507871A (ja) アネキシンａ１投与レジメン
CN110170046A (zh) 成纤维细胞生长因子21在制备治疗急性胰腺炎药物中的应用
CN114569623A (zh) 己酸羟孕酮在制备治疗间质性肺炎的药物中的用途
WO2021142736A1 (en) Dosing regimen of glp-1
Robertson et al. Intravitreal injection of octreotide acetate
US20260014233A1 (en) Multi-dose pen of tirzepatide
HK40094446A (en) Glp-1 dosing regimen
KR20250129611A (ko) 약학 조합물 및 이의 용도
WO2024189054A1 (en) Annexin a1 delayed dosing
HK40128498A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40128497A (zh) 使用gip/glp1共激动剂用於治疗的方法
HK40082881A (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs